Skip to main content

Table 4 Association between anti-Ro52/TRIM21 antibodies and other SSc-related autoantibodies

From: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis

Antibody Prevalence
(N = 963)
Anti-Ro52 antibody positive
(n = 194)
Anti-Ro52 antibody negative
(n = 769)
Pvalues Mean anti-Ro52/TRIM21 titer
(U/ml)
  n % n % n %   
Centromere 334 34.76% 78 40.41% 256 33.33% NS 1,098.64
Topoisomerase I 150 15.58% 19 9.79% 131 17.04% 0.0129 763.28
RNApolIII 144 18.58% 23 15.75% 121 19.24% NS 1,164.47
Pm/Scl 53 6.84% 10 6.85% 43 6.84% NS 1,381.13
U1 RNP 59 6.13% 20 10.31% 39 5.07% 0.0066 2,099.45
CENP-B 285 35.58% 64 42.95% 221 33.90% 0.0372 1,098.86
CENP-A 275 34.33% 61 40.94% 214 32.82% NS 1,019.93
Ro60 53 5.50% 40 20.62% 13 1.69% < 0.0001 5,530.66
SS-B/La 26 2.70% 18 9.28% 8 1.04% < 0.0001 6,003.88
Jo-1 6 0.62% 4 2.06% 2 0.26% 0.0171 4,412.83
Sm 39 4.05% 13 6.70% 26 3.38% 0.0361 1,482.09
Ribosomal P 14 1.45% 3 1.55% 11 1.43% NS 2,088.14
Chromatin 44 4.57% 10 5.15% 34 4.42% NS 1,162.30
  1. NS, not significant.